Clinical trial NCT02279433: A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
Official title: A Phase 1/1B Multi-Center, Non Randomized, Open-Label, Multiple Dose First-In-Human Study Of DS-6051b, An Oral ROS1 And NTRK Inhibitor, In Subjects With Metastatic and/or Unresectable Solid Tumors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Solid Tumors
Keywords: Neoplasms
Lung Neoplasms
Colorectal Neoplasms
Neuroendocrine Tumors
Pancreatic Neoplasms
Lead sponsor: AnHeart Therapeutics Inc.
Sponsor class: INDUSTRY
First posted: 2014-10-31
Enrollment: 46
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: DS-6051b is an orally administered inhibitor of the tyrosine kinases (ROS1) and neurotropic tyrosine kinase receptors (NTRK). This phase 1 first-in-human study evaluates safety and tolerability of DS-6051b in cancer subjects and identify a recommended phase 2 dose (RP2D). In addition, this study will also assess the pharmacokinetic (PK)/pharmacodynamic (PD) profiles and preliminary efficacy of DS-6051b.

Detailed description: The Dose Escalation part (Part 1) of this study will evaluate safety and tolerability, and determine the tentative RP2D. Plasma exposure of DS-6051a and the exposure - QT interval prolongation relationship will also be assessed. Approximately 30 subjects with advanced solid tumors harboring ROS1 or NTRK1, NTRK2, or NTRK3 rearrangement, neuroendocrine carcinoma, or with advanced solid tumors and tumor-induced pain will be enrolled.

The Food Effect (FE) part of this study is to determine the effect of food on the PK of DS-6051a following administration of a single oral dose of DS-6051b. The safety and tolerability of DS-6051b administered with or without food will also be assessed.

After the safety profile of DS-6051b is adequately evaluated, the Dose Expansion part (Part 2) will be initiated to further assess the safety and tolerability, and preliminarily evaluate the efficacy of DS-6051b at the tentative RP2D. Approximately 40 cancer subjects carrying a ROS1 or NTRK1, NTRK2, or NTRK3 rearrangement will be enrolled.

Eligibility criteria: Inclusion Criteria:

1. Histologically or cytologically confirmed diagnosis of advanced solid tumors that have relapsed from or are refractory to standard treatment or for which no standard treatment is available
2. Part 1 Dose Escalation subjects must meet 1 of the following criteria:

   * Solid tumors with documented ROS1, NTRK1, NTRK2, or NTRK3 rearrangement
   * Neuroendocrine tumors
   * Solid tumors with tumor-induced pain
3. Part 2 Dose Expansion subjects must meet 1 of the following criteria:

   * NSCLC with documented ROS1, NTRK1, NTRK2, or NTRK3 rearrangement
   * k-RAS wild-type CRC with documented NTRK1, NTRK2, or NTRK3 rearrangement
   * Other solid tumors with documented ROS1, NTRK1, NTRK2, or NTRK3 rearrangement
   * Pulmonary LCNEC;
4. Male or female ≥18 years of age
5. Eastern Cooperative Oncology Group performance status 0 to 1
6. Adequate organ function
7. Adequate blood clotting function
8. Women of childbearing potential must have a negative pregnancy test
9. Willingness to provide archival tumor samples
10. Other inclusion criteria may apply

Exclusion Criteria:

1. Hematological malignancies
2. Known positive HIV infection, or active hepatitis B or C infection
3. Comorbidity that would interfere with therapy
4. Receipt of an allogeneic bone marrow or allogeneic stem cell transplant
5. Concomitant medical condition that would increase the risk of toxicity, in the opinion of the Investigator or Sponsor
6. History of myocardial infarction and unstable angina within 6 months before study drug treatment; symptomatic congestive heart failure (Congestive Heart Failure New York Heart Association Class III or IV); congenital long QT syndrome; or ventricular arrhythmias defined as grade ≥2 according to NCI CTCAE, v4
7. Clinically active primary central nervous system tumors or brain metastases with the exception of subjects with glioblastoma multiform that carry ROS1 rearrangement
8. Unresolved toxicities from previous anticancer therapy
9. Systemic treatment with anticancer therapy within 3 weeks before study drug treatment
10. Therapeutic radiation therapy or major surgery within 4 weeks before study drug treatment or palliative radiation therapy within 2 weeks before study drug treatment
11. Participation in a therapeutic clinical study within 3 weeks for biological treatments, and within 2 weeks or 5 half-lives, whichever is longer, for small molecule agents, before study drug treatment
12. Concomitant treatment with strong inhibitors or inducers of CYP3A4 and P-glycoprotein
13. Clinically significant malabsorption syndrome or other gastrointestinal disease that would impact drug absorption
14. QTcF values higher than 450 ms at screening
15. Breastfeeding
16. Other exclusion criteria may apply

Primary outcomes:
measure: Part 1: Number of participants with dose-limiting toxicities
timeFrame: within 21 days following the first dose of treatment
measure: Tumor response
timeFrame: up to 2 years
Secondary outcomes:
measure: Maximum concentration (Cmax) for DS-6051a
timeFrame: At Days 1 and 15 of Cycle 1 (21 days)
measure: Time to maximum concentration (Tmax) for DS-6051a
timeFrame: At Days 1 and 15 of Cycle 1 (21 days)
measure: Area under the concentration-time curve from time zero to t (AUC0-t) for DS-6051a
timeFrame: At Days 1 and 15 of Cycle 1 (21 days)
measure: Change from baseline in QTc interval
timeFrame: within 2 years
Other outcomes:
Locations:
city: Scottsdale
country: United States
facility: HonorHealth Research Institute
state: Arizona
city: Orange
country: United States
facility: Chao Family Comprehensive Cancer Center of
state: California
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
city: Boston
country: United States
facility: Dana Farber Cancer Inst.
state: Massachusetts
city: New York
country: United States
facility: New York University
state: New York
city: San Antonio
country: United States
facility: South Texas Accelerated Research Therapeutics
state: Texas
Study officials:
affiliation: AnHeart Therapeutics Inc.
name: Study Director Oncology
role: STUDY_DIRECTOR
References: